Gaudreau, Pierre-Olivier

B cells and tertiary lymphoid structures promote immunotherapy response

Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 2,731

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 966

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 437

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Peng, D. H., Rodriguez, B. L., Diao, L., Gaudreau, P.-O., Padhye, A., Konen, J. M., Ochieng, J. K., Class, C. A., Fradette, J. J., Gibson, L., et al. (2021) · Nature Communications

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 72

CCTG BR.38: Consolidative use of radiotherapy to block (CURB2) oligoprogression in patients with metastatic non–small-cell lung cancer—A randomized phase III trial.

Tsai, C. J., Sun, A., Bradbury, P. A., Schellenberg, D., Bahig, H., Fung, A. S., Bissonnette, J.-P., Das, J. P., Kidane, B., Louie, A. V., et al. (2026) · Journal of Clinical Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 0